Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)

Cinzia Scavullo; Federica Servida; Daniele Lecis; Francesco Onida; Carmelo Drago; Luca Ferrante; Pierfausto Seneci; Wilma Barcellini; Marta Lionetti; Katia Todoerti; Antonino Neri; Domenico Delia; Giorgio Lambertenghi Deliliers

doi:10.1016/j.leukres.2013.03.016

Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)

Cinzia Scavullo, Federica Servida, Daniele Lecis, Francesco Onida, Carmelo Drago, Luca Ferrante, Pierfausto Seneci, Wilma Barcellini, Marta Lionetti, Katia Todoerti, Antonino Neri, Domenico Delia, Giorgio Lambertenghi Deliliers

Research output: Contribution to journal › Article › peer-review

Abstract

Defective apoptosis is a hallmark of the progression of B chronic lymphocytic leukaemia (B-CLL). Smac-mimetics have been shown to induce apoptosis in several tumours. We describe the in vitro pro-apoptotic activity and regulation of the molecular pathway induced by new Smac-mimetics in B-CLL. The cytotoxic effect was significantly higher in B-CLL samples than in healthy controls. No significant synergistic effect was observed in combined treatment. In conclusion one of our compounds (Smac66), used as monotherapy and not in combination, is highly active against B-CLL cells thus suggesting a promising therapeutic potential as a new class of antileukemic drugs in haematology.

Original language	English
Pages (from-to)	809-815
Number of pages	7
Journal	Leukemia Research
Volume	37
Issue number	7
DOIs	https://doi.org/10.1016/j.leukres.2013.03.016
Publication status	Published - Jul 2013

Keywords

Apoptosis
B-CLL
Caspases
Smac-mimetics
Therapy
TNF

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.leukres.2013.03.016

Cite this

@article{f260018acacd46119be72697cf07632c,

title = "Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)",

abstract = "Defective apoptosis is a hallmark of the progression of B chronic lymphocytic leukaemia (B-CLL). Smac-mimetics have been shown to induce apoptosis in several tumours. We describe the in vitro pro-apoptotic activity and regulation of the molecular pathway induced by new Smac-mimetics in B-CLL. The cytotoxic effect was significantly higher in B-CLL samples than in healthy controls. No significant synergistic effect was observed in combined treatment. In conclusion one of our compounds (Smac66), used as monotherapy and not in combination, is highly active against B-CLL cells thus suggesting a promising therapeutic potential as a new class of antileukemic drugs in haematology.",

keywords = "Apoptosis, B-CLL, Caspases, Smac-mimetics, Therapy, TNF",

author = "Cinzia Scavullo and Federica Servida and Daniele Lecis and Francesco Onida and Carmelo Drago and Luca Ferrante and Pierfausto Seneci and Wilma Barcellini and Marta Lionetti and Katia Todoerti and Antonino Neri and Domenico Delia and Deliliers, {Giorgio Lambertenghi}",

year = "2013",

month = jul,

doi = "10.1016/j.leukres.2013.03.016",

language = "English",

volume = "37",

pages = "809--815",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "7",

}

TY - JOUR

T1 - Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)

AU - Scavullo, Cinzia

AU - Servida, Federica

AU - Lecis, Daniele

AU - Onida, Francesco

AU - Drago, Carmelo

AU - Ferrante, Luca

AU - Seneci, Pierfausto

AU - Barcellini, Wilma

AU - Lionetti, Marta

AU - Todoerti, Katia

AU - Neri, Antonino

AU - Delia, Domenico

AU - Deliliers, Giorgio Lambertenghi

PY - 2013/7

Y1 - 2013/7

N2 - Defective apoptosis is a hallmark of the progression of B chronic lymphocytic leukaemia (B-CLL). Smac-mimetics have been shown to induce apoptosis in several tumours. We describe the in vitro pro-apoptotic activity and regulation of the molecular pathway induced by new Smac-mimetics in B-CLL. The cytotoxic effect was significantly higher in B-CLL samples than in healthy controls. No significant synergistic effect was observed in combined treatment. In conclusion one of our compounds (Smac66), used as monotherapy and not in combination, is highly active against B-CLL cells thus suggesting a promising therapeutic potential as a new class of antileukemic drugs in haematology.

AB - Defective apoptosis is a hallmark of the progression of B chronic lymphocytic leukaemia (B-CLL). Smac-mimetics have been shown to induce apoptosis in several tumours. We describe the in vitro pro-apoptotic activity and regulation of the molecular pathway induced by new Smac-mimetics in B-CLL. The cytotoxic effect was significantly higher in B-CLL samples than in healthy controls. No significant synergistic effect was observed in combined treatment. In conclusion one of our compounds (Smac66), used as monotherapy and not in combination, is highly active against B-CLL cells thus suggesting a promising therapeutic potential as a new class of antileukemic drugs in haematology.

KW - Apoptosis

KW - B-CLL

KW - Caspases

KW - Smac-mimetics

KW - Therapy

KW - TNF

UR - http://www.scopus.com/inward/record.url?scp=84878499550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878499550&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.03.016

DO - 10.1016/j.leukres.2013.03.016

M3 - Article

C2 - 23618690

AN - SCOPUS:84878499550

VL - 37

SP - 809

EP - 815

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -

Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this